Kanzhun Limited (BZ)
NASDAQ: BZ · Real-Time Price · USD
21.49
-0.95 (-4.23%)
Aug 14, 2025, 10:25 AM - Market open
Marinus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts that cover Marinus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $17.67, which forecasts a -17.78% decrease in the stock price over the next year. The lowest target is $15 and the highest is $22.
Price Target: $17.67 (-17.78%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 13, 2025.
Analyst Ratings
The average analyst rating for Marinus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $16 → $22 | Buy | Maintains | $16 → $22 | +2.37% | Mar 13, 2025 |
| Barclays | Barclays | Buy Maintains $14 → $16 | Buy | Maintains | $14 → $16 | -25.55% | Dec 9, 2024 |
| Bernstein | Bernstein | Buy → Hold Downgrades $15 | Buy → Hold | Downgrades | $15 | -30.20% | Dec 9, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $17 → $16 | Strong Buy | Maintains | $17 → $16 | -25.55% | Nov 29, 2024 |
| Barclays | Barclays | Buy Maintains $27 → $14 | Buy | Maintains | $27 → $14 | -34.85% | Aug 30, 2024 |
Financial Forecast
Revenue This Year
8.46B
from 7.36B
Increased by 14.96%
Revenue Next Year
9.57B
from 8.46B
Increased by 13.22%
EPS This Year
7.53
from 3.48
Increased by 116.48%
EPS Next Year
8.59
from 7.53
Increased by 14.09%
Financial currency is CNY. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.8B | 10.3B | 11.8B | ||
| Avg | 8.5B | 9.6B | 10.7B | ||
| Low | 7.9B | 8.8B | 9.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.5% | 22.0% | 22.9% | ||
| Avg | 15.0% | 13.2% | 11.9% | ||
| Low | 7.9% | 3.5% | -0.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 7.98 | 9.89 | 12.08 | |
| Avg | 7.53 | 8.59 | 9.80 | |
| Low | 6.88 | 7.64 | 8.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 129.3% | 31.3% | 40.5% | |
| Avg | 116.5% | 14.1% | 14.1% | |
| Low | 97.7% | 1.5% | -3.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.